Key Developments

On May 23, 2024, DelSiTech Ltd, Clinical-stage drug delivery and development company, announced that the company has entered into a Licensing Agreement with an undisclosed global pharmaceutical company. Under the terms of agreement, DelSiTech grants an exclusive global license to DelSiTech's Silica Matrix based, controlled release technology for development and commercialization of an undisclosed long-acting injectable drug product.
On March 14, 2024, Evonik, specialty chemicals company, announced that they had launched EUDRAGIT for targeted drug delivery.
In October 2023, Assistant Professor Jie Feng has been awarded funding from the National Science Foundation to further his research efforts aimed at improving targeted drug delivery and controlled release of therapeutics with active lipid vesicles. Feng’s proposed project, “Unlocking the Potential of Active Lipid Vesicles for Directed Delivery and Controlled Release of Therapeutic Payloads,” will be funded by nearly $500k and is in collaboration with On Shun Pak of Santa Clara University.
In March 2022, Eucure Biopharma, a subsidiary of Biocytogen, announced that the first patient dosing for a phase I multi-regional clinical trials of YH002 (anti-OX40 monoclonal antibody) in combination with YH001 in Austria.